Pancreatic Cancer Patients No Longer Need Expanded Access to Get a RAS Inhibitor After Federal Approval

FDA approved daraxonrasib for metastatic pancreatic adenocarcinoma, replacing a case by case expanded access route with a prescribable therapy.

Have A Referral?